Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 19 for:    Recruiting, Not yet recruiting, Available Studies | Pain | Neurostimulation

To Study and Evaluate the Effectiveness of Treatment by Percutaneous Electrical NeuroStimulation (PENS) for Post-operative Pain in Cesarean Section Patients Using Primary Relief v 2.0 (POPS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03829774
Recruitment Status : Recruiting
First Posted : February 4, 2019
Last Update Posted : February 4, 2019
Sponsor:
Information provided by (Responsible Party):
DyAnsys, Inc.

Brief Summary:
To study and evaluate the Effectiveness of Treatment by Percutaneous Electrical NeuroStimulation (PENS) for post-operative pain in Cesarean Section patients using First Relief

Condition or disease Intervention/treatment Phase
Cesarean Section; Dehiscence Device: Primary Relief v 2.0 Drug: Paracetamol Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: To Study and Evaluate the Effectiveness of Treatment by Percutaneous Electrical NeuroStimulation (PENS) for Post-operative Pain in Cesarean Section Patients Using Primary Relief v 2.0
Actual Study Start Date : January 2, 2019
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : July 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cesarean Section

Arm Intervention/treatment
Experimental: Primary Relief v 2.0 Device
The test product or device called Primary Relief v 2.0 device will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
Device: Primary Relief v 2.0
The test product or device called Primary Relief v 2.0 will be used for the study. The study will be conducted for a period of two to three months with the treatment period of 3 - 4 days i.e single treatment (installation). The additional time taken will be to define the characteristics of the patient population and to recruit appropriate patients. Finally, there will be a data analysis and report writing period. Overall, the study is expected to 3 months. The device will be placed onto the auricle part of the ear for percutaneous electrical nerve stimulation.
Other Name: Percutaeneous Nerve Field Stimulator Neurostimulator

Placebo Comparator: Paracetamol
A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous Paracetamol , 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
Drug: Paracetamol
A control group, receiving a standard treatment as follows: primary choice of analgesic was intravenous paracetamol, 1 gram, and if the pain relief was inadequate, diclofenac inj. If pain persisted in spite of these measures, 50 mg tramadol was administered intravenously
Other Name: Standard Drug Treatment for Postoperative pain




Primary Outcome Measures :
  1. assessing the effects of PENS therapy in Postoperative period of Lower Segment Caesarean Section pain using VAS score. [ Time Frame: 2 hours of device activation ]
    To assess the effects of PENS therapy in Post-Operative period of Lower Segment Caesarean Section pain using the Visual Analogue Scale measurement. The level of pain is calculated from the VAS (Visual Analogue Scale) before the device is installed and assessed after 2 hours of the device activation. The pain level should be decreased when assessing after 2 hours of device installation. The score should be below 5. where 0 being no pain, 5 being moderate and 10 being maximum pain.


Secondary Outcome Measures :
  1. Evaluate the impact of this treatment in terms of Quality Of Life [ Time Frame: 2nd day ]
    whether treatment can negate the need for more complex surgical treatments and/or reduce the need for drug treatment. Change in quality of life will be measured using the Evaluation form measurement.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Pregnant Women willing to undergo C-Section
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age range between 22 - 35 years
  2. Patient willing to undergo C-section surgery
  3. Patient having pains after one hour of post C-Section surgery
  4. Patients who is conscious and oriented for device installation after anesthetic effect
  5. Patient who completed required clinical and biochemical investigations as deemed necessary by the gynecologist after post C - section surgery.
  6. No previous poor obstetrical outcome
  7. No experience in Han's Acupoint nerve stimulator and TENS for other reasons.
  8. Term pregnancy (> 37 weeks of gestation).
  9. Understands and is willing to participate in the clinical study and can comply with study procedures.
  10. Normal cognitive and communicative ability as judged by clinical assessment and ability to complete self-reported questionnaires.

Exclusion Criteria:

  1. Had been diagnosed with other diseases such as preoperative presence of maternal mental, neurological disease, affecting evaluation of pains and disease condition.
  2. Had combined with gestational hypertension, gestational diabetes, gestational thyroid disease.
  3. Had taken analgesic drugs
  4. Had used diazepam, piperazine hydrochloride or other sedative, analgesic drugs in the stage of labor.
  5. Were overweight or low pregnancy weight, Body mass index (< 18.5 or >25 kg/m2).
  6. Patients who are not agreeing to receive painless labor and not sign the informed consent form.
  7. Neonatal problem requiring immediate separation from the mother for medical care or NICU admittance.
  8. Severe placental abruption.
  9. Hydrops (accumulation of fluid or edema in fetus body tissue and cavities) if secondary to anemia or heart failure.
  10. Known twin to twin transfusion syndrome (TTS).
  11. Congenital anomalies that may hamper the procedure (gastroschisis, amphalacele, spina bifida).
  12. Home birth.
  13. Severe mental health problem
  14. Hearing impairment.
  15. Legal abortion
  16. Twin pregnancy
  17. Instrumental birth
  18. Uterine anomalies with contraindication for vaginal birth. Eg: previous opening of uterine cavity, myomectomy, congenital abnormalities.
  19. Placenta anomalies.
  20. Placenta praevia, suspected acreta, increta, percreta especially after previous caesarean.
  21. Fetal abnormalities, growth restriction.
  22. Maternal complication with surgery.
  23. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening; or subject or physician anticipates use of any of these therapies by the subject during the course of the study
  24. Previous participation in the Treatment Phase of this Protocol
  25. Malignant disease not in remission for five years or more that has been medically or surgically treated without evidence of metastases
  26. Presence of one or more medical conditions, as determined by medical history, which seriously compromises the subject's ability to complete the study, including history of poor adherence with medical treatment, unstable pain intensity or pain medications 6 weeks prior to the study, renal, hepatic, hematologic, active auto-immune or immune diseases that, in the opinion of the Investigator, would make the subject an inappropriate candidate for this study: a) One or more abnormal blood biochemistry analyte result that is ≥ 3 times that of the upper limit of the normal range
  27. Known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV)
  28. American Heart Association (AHA) Class III and IV congestive heart failure (CHF), as defined by the following criteria: a) Class III: Symptoms with moderate exertion b) Class IV: Symptoms at rest or c) Cardiac pacemakers.
  29. Subjects with a diagnosis of psychiatric disorders such as major depressive disorder, bipolar disorder, obsessive compulsive disorder, generalized anxiety, dysthymia or suicidality/suicide ideation
  30. Subjects not willing to undergo treatment before discharge from the hospital.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03829774


Contacts
Layout table for location contacts
Contact: Balachandran V, MD +91 9946452707 v.balachandran@dyansys.com
Contact: Hariharan A, B.Tech +91 8124147672 a.hariharan@dyansys.com

Locations
Layout table for location information
India
Clinic Recruiting
Warangal, Telangana, India, 506002
Contact: Balachandran V, MD    9496452707    v.balachandaran@dyansys.com   
Contact: Robin M, GNM    8722627172      
Sponsors and Collaborators
DyAnsys, Inc.

Layout table for additonal information
Responsible Party: DyAnsys, Inc.
ClinicalTrials.gov Identifier: NCT03829774     History of Changes
Other Study ID Numbers: CS/PRv2.0/C-Sec/2019
First Posted: February 4, 2019    Key Record Dates
Last Update Posted: February 4, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pain, Postoperative
Pain
Postoperative Complications
Pathologic Processes
Neurologic Manifestations
Signs and Symptoms
Acetaminophen
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics